PHAXIAM THERAPEUTICS S.A. PHAXIAM Therapeutics S.A. Stock Euronext Paris
Equities
PHXM
FR0011471135
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.95 EUR | +1.20% |
|
0.00% | -35.87% |
| Sales 2024 * | 1.05M 1.13M | Sales 2025 * | 1.6M 1.72M | Capitalization | 17.92M 19.23M |
|---|---|---|---|---|---|
| Net income 2024 * | - 0 | Net income 2025 * | 1M 1.07M | EV / Sales 2024 * | 17.5 x |
| Net Debt 2024 * | 450K 483K | Net Debt 2025 * | 10.55M 11.32M | EV / Sales 2025 * | 17.8 x |
| P/E ratio 2024 * |
-2.07
x | P/E ratio 2025 * |
-3.07
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.14% |
More Fundamentals
* Assessed data
More news
Latest transcript on PHAXIAM Therapeutics S.A.
More press releases
More news
| 1 week | +1.20% | ||
| Current month | -1.01% | ||
| 1 month | +1.72% | ||
| 3 months | -28.14% | ||
| 6 months | -30.83% | ||
| Current year | -35.87% |
1 week
2.88
2.95
1 month
2.843.00
3 years
2.6075.80
5 years
2.60114.60
10 years
2.60402.00
| Managers | Title | Age | Since |
|---|---|---|---|
Thibaut du Fayet
CEO | Chief Executive Officer | 56 | 23-06-22 |
Eric Soyer
DFI | Director of Finance/CFO | 57 | 23-06-22 |
Pascal Birman
CTO | Chief Tech/Sci/R&D Officer | - | 23-06-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 23-06-22 | |
Hilde Windels
BRD | Director/Board Member | 59 | 23-06-22 |
Gil Beyen
BRD | Director/Board Member | 62 | 23-06-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 2.95 | +1.20% | 941 |
| 24-04-24 | 2.915 | -0.17% | 1,540 |
| 24-04-23 | 2.92 | -0.68% | 1,047 |
| 24-04-22 | 2.94 | +0.68% | 731 |
| 24-04-19 | 2.92 | +0.17% | 4,229 |
Real-time Euronext Paris, April 25, 2024 at 11:35 am EDT
More quotes
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
2024-05-14
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.915
EUR
Average target price
6.85
EUR
Spread / Average Target
+134.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.26% | 104B | |
| +1.41% | 97.42B | |
| +0.79% | 22.2B | |
| -17.84% | 21.23B | |
| -11.11% | 18.33B | |
| -42.83% | 16.35B | |
| -17.63% | 15.06B | |
| +4.55% | 13.98B | |
| +32.11% | 11.66B |
- Stock Market
- Equities
- PHXM Stock
- PHXM Stock
